Alpha-1 Antitrypsin Deficiency Market

Alpha-1 Antitrypsin Deficiency Market Size and Share Forecast Outlook (2023 to 2033)

The global Alpha-1 antitrypsin deficiency market is likely to garner a market value of USD 3 Billion in 2023 and is expected to reach USD 10 Billion by registering a CAGR of 12.8% in the forecast period 2023 to 2033.

One of the primary reasons driving market expansion is the rising frequency of respiratory illnesses. Furthermore, the increased utilization of augmentation treatment is propelling market expansion.

This therapy includes extracting AAT protein from the blood plasma of a healthy donor in order to increase AAT levels in patients' respiratory tracts. In accordance with this, this treatment also slows the advancement of emphysema, reduces the frequency of exacerbations, and speeds up recovery time, all of which contribute to its growing popularity among both patients and healthcare professionals.

Increased personal disposable income and increased knowledge in developing nations about the availability of treatment choices will provide even more attractive market development potential. Rising worldwide medical tourism, an increase in the prescription for combination medicines, and a high potential for development in the undeveloped market will provide enough market growth possibilities.

Data Points	Key Statistics
Expected Market Value (2023)	USD 3 Billion
Anticipated Forecast Value (2033)	USD 10 Billion
Projected Growth Rate (2023 to 2033)	12.8% CAGR

Comparison of 2018 to 2022 Demand vs 2023 to 2033 Outlook for Alpha-1 Antitrypsin Deficiency

The global demand for alpha-1 antitrypsin deficiency is projected to increase at a CAGR of 12.8% during the forecast period between 2023 and 2033, reaching a total of USD 10 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 10%.

Numerous technical breakthroughs in diagnostic procedures and the development of novel technologies for the synthesis and purification of AAT. They are of higher grade and devoid of impurities such as viruses and germs. Other factors, such as increased Research and Development efforts and advancements in medical infrastructure, are expected to propel the market even more.

Key Drivers Fueling Growth in the Alpha-1 Antitrypsin Deficiency Market

Increasing Research and Development Activities to Accelerate Market Growth

The increasing number of strategic collaborations between public and private market participants is driving an increase in the amount of Research and Development activities on a daily basis. These capabilities are being applied to the creation of innovative pharmaceuticals and medical technologies, which will drive the need for alpha1-antitrypsin deficiency therapy.

Furthermore, an increase in the number of genetic testing, blood tests, and biopsy tests, increased attempts by public and private groups to raise awareness, and a well-organized distribution network of top manufacturers will all contribute to the market's growth rate. Other factors, such as increased demand for effective medicines and expanding use of early diagnostic methods, will have a beneficial impact on the market's growth rate.

Increasing Healthcare Infrastructure Investment

Another key element impacting the growth rate of the alpha1-antitrypsin market is increased healthcare spending, which aids in infrastructure improvement. The expansion and growth of the healthcare business, particularly in developing nations, would encourage the usage and deployment of new and sophisticated medical technology, equipment, and pharmaceuticals. This will immediately boost the need for therapy of alpha1-antitrypsin deficiency.

Challenges and Low-Growth Areas in the Alpha-1 Antitrypsin Deficiency Market

Huge Investments in Research and Development to Stymie Market Augmentation

High expenses connected with research and development capabilities will emerge as one of the market's most significant limitations. The lack of knowledge and necessary infrastructure in developing and backward nations, as well as sluggish diagnostic rates of alpha1-antitrypsin deficiency, may further derail the market expansion. The slow pace of approval for medications and inhibitors, the scarcity of plasma fractionation capacity, and the rising number of patent expirations will all provide challenges to the market's growth rate.

Analysis of Regional Trends Influencing Alpha-1 Antitrypsin Deficiency Diagnosis and Treatment

How will Alpha-1 Antitrypsin Deficiency Market Demand progress in the Asia Pacific?

Rising Healthcare Expenditure to Widen Profit Margins

Asia Pacific encompasses nations with a big patient pool and a high elderly population, thus the alpha1-antitrypsin deficiency industry in that region is driven by this factor. Over the projection period, the Asia Pacific regional sector is predicted to increase at a rapid pace.

The constant development of the medical tourism industry, rising healthcare expenditure, and bigger government initiatives pertaining to the development of healthcare infrastructure, primarily biotechnology, agriculture, and pharmacology, are just a few of the factors contributing to the rapid growth of the Asia Pacific alpha1-antitrypsin deficiency market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 12% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Alpha-1 Antitrypsin Deficiency in North America?

Presence of Established Healthcare Infrastructure to Drive Market

The bulk of the worldwide alpha1-antitrypsin deficiency market was accounted for by North America. Because of the growing number of genetic disease therapeutics clinical trials in the area, North America is ruling the alpha1-antitrypsin deficiency market.

The presence of established healthcare infrastructure in the region, the availability of qualified specialists and advanced genetic testing equipment, high healthcare spending, and superior reimbursement rules are key reasons contributing to its substantial share. North America is expected to grow at a CAGR of 12.7% in the assessment period 2023-2033.

What Factors favoring the Growth of Alpha-1 Antitrypsin Deficiency in Europe?

Expanding Patient Pool to fuel Market Growth

Because of the region's abundance of qualified specialists and modern genetic testing equipment, Europe is the second largest market for the alpha1-antitrypsin deficiency industry.

Europe is expected to develop at the fastest rate throughout the projection period owing to an expanding patient pool and more government backing. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 12.3% in the assessment period 2023 to 2033.

Alpha-1 Antitrypsin Deficiency Industry Analysis by Top Investment Segments

Which is the Most Popular Product Type in the Alpha-1 Antitrypsin Deficiency Market?

Corticosteroid-based Treatments are highly sought after

The increased prevalence of chronic illnesses, an aging population, and rising Research and Development spending are the primary drivers of the corticosteroid segment's rise. The worldwide burden of chronic illnesses is expected to rise dramatically in the future years.

Furthermore, the growing senior population is more prone to chronic diseases that necessitate corticosteroid therapy for a number of ailments, which may drive the corticosteroid sector in the coming years further driving the Alpha-1 Antitrypsin Deficiency market.

Which is the Most Preferred Application in the Alpha-1 Antitrypsin Deficiency Market?

Hospitals to be Primary Centers for Disbursing Treatments

In terms of application, hospitals led the Alpha-1 Antitrypsin Deficiency market in 2022. Patients mostly desire to be admitted to the hospital for therapy.

Moreover, the availability of highly experienced medical personnel who give a superior treatment experience has contributed to the rising market share over the next several years.

Emerging Start-Ups Innovating in the Alpha-1 Antitrypsin Deficiency Market

Key start-up players in the automotive axles are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Alpha-1 Antitrypsin Deficiency start-ups are as follows:

• Lexeo Therapeutics, established in the United States, offers gene therapy for degenerative diseases. LX2006, the company's main medication, is an AAV-mediated therapy that treats Friedreich's ataxia (FA), a multi-system illness that affects cardiovascular functioning. LX1004 and LX1001 are two other medicines in the startup's repertoire. The former introduces neuronal ceroid lipofuscinosis 2 (CLN2) into the central nervous system, whereas the latter introduces APOE2. Both medicines are in clinical trials and are aimed towards Batten disease and Alzheimer's disease, respectively.
• Genespire is an Italian biotech company that is working on gene therapy for hereditary metabolic diseases. X-linked hyper IgM syndrome (X-HIGM) is an uncommon and potentially fatal immunological weakness. The startup's solution uses sophisticated gene editing to combat X-HIGM. This method restores the functional expression of the endogenous faulty gene, enhancing patients' immunological responses. In addition, the company provides lentiviral vector technology for off-the-shelf, in vivo gene therapy for liver ailments.
• Vivet Therapeutics, a French firm, is developing a gene replacement treatment for Wilson's disease. A mutation in the ATP7B copper transporter causes hazardous copper buildup in the living and central nervous systems. The medicine developed by the company restores physiological copper metabolism by a single intravenous vector injection. This eliminates the need for many daily doses of existing medications. Furthermore, it removes the negative effects associated with existing medication and improves adherence to treatment. The company is also working on treatments for progressive familial intrahepatic cholestasis (PFIC) and Citrullinemia type I (CTLN1).

Competitive Outlook for the Alpha-1 Antitrypsin Deficiency Industry

Key players in the Alpha-1 Antitrypsin Deficiency market are Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline, CSL Behring, and LFB Biomedicaments.

Recent Developments:

• In October 2022, Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced that it has been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, for an estimated total value of USD 22 Million. This award ensures that such items will continue to be sold on the Canadian market.
• In May 2022, Boehringer Ingelheim announced that ArisGlobal has acquired its digital invention, BRASS. This data insights engine will be incorporated into ArisGlobal's LifeSphere® technology platform as LifeSphere Clarity and will play a critical role in driving industry-wide progress of pharmacovigilance and patient safety.

Scope of the Alpha-1 Antitrypsin Deficiency Market Report

Report Attribute	Details
Market Value in 2023	USD 3 Billion
Market Value in 2033	USD 10 Billion
Growth Rate	CAGR of 12.8% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Product, Application, Region
Regions Covered	North America; Latin America; Europe; Asia Pacific; Middle East and Africa (MEA)
Key Countries Profiled	The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC, South Africa, Israel
Key Companies Profiled	Pfizer; Baxter; AstraZeneca; Grifols; Teva Pharmaceutical Industries; Boehringer Ingelheim; Kamada Ltd; GlaxoSmithKline; CSL Behring; LFB Biomedicaments
Customization	Available Upon Request

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
• 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
  • 5.1. Augmentation Therapy
  • 5.2. Bronchodilators
  • 5.3. Corticosteroids
  • 5.4. Oxygen Therapy
• 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
  • 6.1. Hospitals
  • 6.2. Specialty Clinics
  • 6.3. Pharmacies
• 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
  • 7.1. North America
  • 7.2. Latin America
  • 7.3. Europe
  • 7.4. Asia Pacific
  • 7.5. Middle East & Africa (MEA)
• 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
• 13. Key Countries Market Analysis
• 14. Market Structure Analysis
• 15. Competition Analysis
  • 15.1. Pfizer
  • 15.2. Baxter
  • 15.3. AstraZeneca
  • 15.4. Grifols
  • 15.5. Teva Pharmaceutical Industries
  • 15.6. Boehringer Ingelheim
  • 15.7. Kamada Ltd
  • 15.8. GlaxoSmithKline
  • 15.9. CSL Behring
  • 15.10. LFB Biomedicaments
• 16. Assumptions & Acronyms Used
• 17. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: MEA Market Value (US$ Million) Forecast by Product, 2018 to 2033

Table 18: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033

List of Figures

Figure 1: Global Market Value (US$ Million) by Product, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 13: Global Market Attractiveness by Product, 2023 to 2033

Figure 14: Global Market Attractiveness by Application, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Product, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Application, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 28: North America Market Attractiveness by Product, 2023 to 2033

Figure 29: North America Market Attractiveness by Application, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Product, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Application, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Product, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Application, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Product, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Application, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 58: Europe Market Attractiveness by Product, 2023 to 2033

Figure 59: Europe Market Attractiveness by Application, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Product, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Product, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by Application, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: MEA Market Value (US$ Million) by Product, 2023 to 2033

Figure 77: MEA Market Value (US$ Million) by Application, 2023 to 2033

Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: MEA Market Value (US$ Million) Analysis by Product, 2018 to 2033

Figure 83: MEA Market Value Share (%) and BPS Analysis by Product, 2023 to 2033

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033

Figure 85: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 86: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 88: MEA Market Attractiveness by Product, 2023 to 2033

Figure 89: MEA Market Attractiveness by Application, 2023 to 2033

Figure 90: MEA Market Attractiveness by Country, 2023 to 2033